Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial

ConclusionRomosozumab/denosumab in Japanese subjects at high risk of fracture resulted in significant BMD gains and numerically lower vertebral fracture rate vs. placebo/denosumab at all timepoints measured.

http://link.springer.com/10.1007/s00774-020-01147-5

Source: Journal of Bone and Mineral Metabolism - October 15, 2020 Category: Orthopaedics Source Type: research